PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Published:2019-06-11 Issue:9 Volume:42 Page:1724-1732
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:Dia Care

Author:

Aroda Vanita R.^ORCID,Rosenstock Julio^ORCID,Terauchi Yasuo^ORCID,Altuntas Yuksel,Lalic Nebojsa M.,Morales Villegas Enrique C.,Jeppesen Ole K.,Christiansen Erik,Hertz Christin L.,Haluzík Martin^ORCID

Funder

Novo Nordisk A/S

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference25 articles.

1. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018

2. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

3. U.S. Food and Drug Administration. Ozempic – Highlights of prescribing information [Internet], 2017. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Accessed 14 November 2018

4. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

5. Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weight Loss Pharmacotherapy;Gastrointestinal Endoscopy Clinics of North America;2024-10

2. Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program;Diabetes, Obesity and Metabolism;2024-09-09

3. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article;Indian Journal of Endocrinology and Metabolism;2024-09-04

4. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study;Diabetes, Obesity and Metabolism;2024-09-02

5. Obesity and cardiovascular disease: an ESC clinical consensus statement;European Journal of Preventive Cardiology;2024-08-30